I
IMRX
Immuneering Corp
5.18
-0.12-2.26%After Hours: 5.18 0.00 0.00%19:30 08/24 EDT
OPEN/PREV CLOSE5.31/5.30
TODAY RANGE5.13-5.35
VOL400.57K
MARKET CAP335.13M
52 WEEK RANGE3.860-10.08
AVG VOL (3M)1.33M
% TURNOVER0.62%
TURNOVER--
P/E (TTM)-5.0242
% RANGE4.06%
EPS(TTM)-1.0310
P/E(FORWARD)-4.6562
P/B1.757
BVPS2.948
DIVIDEND--
P/S4,050.00
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP288.50M
SHARES OUTSTANDING64.70M
NEXT EARNINGS--
FREE FLOAT55.69M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Benzinga·08/06 14:12
This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday
TipRanks·08/06 13:51
Zillow downgraded, Global Payments upgraded: Wall Street’s top analyst calls
Dow Jones·08/06 11:16
Immuneering Price Target Announced at $14.00/Share by HC Wainwright & Co.
Dow Jones·08/06 11:16
Immuneering Initiated at Buy by HC Wainwright & Co.
TipRanks·08/06 10:11
Immuneering initiated with a Buy at H.C. Wainwright
TipRanks·08/05 14:26
Immuneering reports Q2 EPS 927c), consensus (27c)
Seeking Alpha·08/05 11:43
Immuneering GAAP EPS of -$0.27 in-line
Benzinga·08/05 11:38
Immuneering Q2 EPS $(0.27), Inline
Dow Jones·08/05 11:31
*Immuneering Expects Cash Runway to Be Sufficient to Fund Ops Into 2029 >IMRX
Dow Jones·08/05 11:30
*Immuneering 2Q Loss/Shr 27c >IMRX
Seeking Alpha·07/27 22:04
Immuneering: A Third (Much Cheaper) Way To Invest In The RAS-RAF-MEK-ERK 'Revolution'
TipRanks·07/21 21:10
Immuneering publishes preclinical data on atebimetinib in Cancer Research
Same Industry
Name/Symbol
Change%
Price